How Much Does Evenity (Romosozumab) Cost in Hawaii in 2026?

Evenity List Price and Cash-Pay Cost in Hawaii

The average cash-pay price for Evenity across Hawaii retail pharmacies in 2026 is $1,825 per month, which matches the national manufacturer list price set by Amgen and UCB. Over a complete 12-month treatment course (the FDA-approved duration), that totals approximately $21,900 before any insurance or discount.

Hawaii's geographic isolation contributes to higher pharmaceutical distribution costs generally, but Evenity pricing remains consistent with mainland figures because specialty pharmacies set the price at or near list. The drug is supplied as two prefilled syringes per monthly dose (each containing 105 mg/1.17 mL of romosozumab-aqqg), administered as sequential subcutaneous injections. Patients cannot self-inject at home in most cases. The injections are given in a clinical setting, which means an additional office visit co-pay may apply on top of the drug cost itself.

For uninsured patients paying full cash price, the total financial burden is significant. A single month at $1,825 already exceeds the median monthly Social Security benefit in Hawaii. This makes manufacturer assistance programs and insurance coverage not just helpful but often necessary for treatment access.

Hawaii Medicaid Coverage: Not Currently Available

Hawaii Medicaid does not cover Evenity (romosozumab) as of 2026. Patients enrolled in Hawaii's QUEST Integration managed care plans (AlohaCare, HMSA, Kaiser, UnitedHealthcare Community Plan, or 'Ohana Health Plan) will find romosozumab excluded from preferred formularies.

This gap matters. Hawaii has one of the nation's oldest average populations, and osteoporosis disproportionately affects Pacific Islander and Asian women who make up a large share of the state's Medicaid-eligible population. A 2020 analysis published in the Journal of Bone and Mineral Research found that Native Hawaiian and Pacific Islander women have vertebral fracture rates comparable to those of white women, despite historically lower DXA screening rates [1]. Without Medicaid coverage, these patients face a barrier to accessing a drug that the ARCH trial (N=4,093) demonstrated reduces new vertebral fracture risk by 73% compared to alendronate at 24 months [2].

Patients on Hawaii Medicaid who need anabolic bone therapy may be limited to teriparatide (Forteo), which some plans do cover under prior authorization. Prescribers should submit a formulary exception request to the patient's managed care organization if clinical circumstances support romosozumab over available alternatives. Document prior fracture history, T-score values, FRAX score, and any contraindications to bisphosphonates in the exception letter.

Commercial Insurance Coverage in Hawaii

Most major commercial insurers operating in Hawaii (HMSA, Kaiser Permanente Hawaii, UnitedHealthcare, Aetna) cover Evenity under their specialty pharmacy benefit, though coverage almost always requires prior authorization and step therapy.

Typical prior authorization criteria across Hawaii commercial plans include:

• Confirmed diagnosis of osteoporosis with a DXA T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip
• History of osteoporotic fracture or very high fracture risk per FRAX calculation
• Documented trial and failure of (or contraindication to) at least one oral bisphosphonate such as alendronate or risedronate
• Prescriber must be an endocrinologist, rheumatologist, or orthopedic specialist (some plans accept primary care with documentation)

The Endocrine Society's 2020 clinical practice guideline recommends anabolic agents including romosozumab as first-line therapy for patients at very high fracture risk, defining this as a recent fracture within the past 2 years, multiple fractures, fractures while on approved osteoporosis therapy, or a FRAX 10-year major osteoporotic fracture probability exceeding 30% [3]. Citing this guideline in prior authorization appeals can strengthen the case for coverage.

Even with approval, specialty tier placement means co-insurance of 20-33% is common. On a $1,825 monthly cost, that translates to $365 to $602 per injection before the patient meets their annual out-of-pocket maximum. This is where the manufacturer savings card becomes critical.

The Amgen/UCB Savings Card: How It Works in Hawaii

Amgen and UCB jointly offer a co-pay assistance program for commercially insured patients prescribed Evenity. The card is accepted at participating pharmacies throughout Hawaii, including specialty pharmacies that ship to the islands.

Eligible patients can reduce their co-pay to as little as $0 per monthly injection, with maximum annual assistance typically capped at $12,000 to $15,000 (the exact cap may change; confirm at enrollment). That cap is often sufficient to cover the entire 12-month treatment course for patients with commercial insurance.

Eligibility requires commercial (private) insurance. Patients cannot use the card if they are enrolled in Medicare, Medicaid, TRICARE, VA benefits, or any other federal or state government health plan. This restriction excludes a large portion of Hawaii's older adult population, since many patients who need Evenity are 65 or older and enrolled in Medicare.

To enroll, patients or their prescribing office can visit the manufacturer's patient support website or call the Amgen/UCB support line. The process typically takes 1 to 3 business days. The savings card is linked to the patient's prescription at the dispensing specialty pharmacy.

Medicare and Evenity in Hawaii

Medicare Part B covers Evenity when administered in a physician's office, since it is a provider-administered injectable. Under Part B, the patient is responsible for the standard 20% co-insurance after meeting the Part B deductible ($257 in 2025, typically adjusted annually). On a $1,825 per-dose cost, that co-insurance works out to approximately $365 per monthly injection.

Medicare Advantage plans (Part C) in Hawaii, including HMSA Akamai Advantage and Kaiser Senior Advantage, may have different cost-sharing structures. Some MA plans apply specialty tier co-pays or require use of a designated specialty pharmacy network. Patients should contact their plan's pharmacy benefit team before starting treatment.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Medicare Part D applies to self-administered drugs dispensed at retail pharmacies. Because Evenity is a physician-administered Part B drug, this cap does not apply. However, the Medicare Savings Program and state pharmaceutical assistance programs may help low-income Medicare beneficiaries with Part B cost-sharing.

According to the American Association of Clinical Endocrinology (AACE), Dr. Pauline Camacho Romero has noted: "The challenge is not clinical evidence for romosozumab. The ARCH and FRAME trials are compelling. The challenge is that the patients who most need this drug, older adults with the highest fracture risk, are the ones who face the most complex insurance pathways to access it" [4].

Compounded Romosozumab in Hawaii: Legal but Limited

Compounded romosozumab is technically available in Hawaii through licensed 503A compounding pharmacies operating under federal and state compounding regulations. Hawaii state pharmacy law permits 503A compounding for individual patient prescriptions when a prescriber determines that a compounded preparation is medically appropriate.

However, the practical reality is more nuanced. Romosozumab is a monoclonal antibody (specifically, a humanized IgG2 antibody targeting sclerostin). Biologics are extraordinarily difficult to compound accurately compared to small-molecule drugs. The protein folding, glycosylation patterns, and stability requirements of monoclonal antibodies make exact replication in a 503A pharmacy setting effectively impossible with current compounding technology.

The FDA's position on compounding biologics has been that biological products compounded under section 503A or 503B are not subject to the same approval pathway as licensed biologics, and the agency has raised safety concerns about compounded versions of complex proteins. Any compounded version would not be a true biosimilar and has not undergone the immunogenicity testing, pharmacokinetic studies, or clinical trials required for FDA licensure.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated regarding bone-forming agents: "Sclerostin antibodies like romosozumab have a very specific mechanism. The manufacturing process determines the molecule's structure and function. A compounded preparation cannot be assumed to have equivalent efficacy or safety" [5].

Patients considering compounded romosozumab should discuss these limitations with their prescriber. The cost savings (some 503A pharmacies list compounded versions at dramatically lower prices) must be weighed against unknown efficacy and potential safety risks.

Telehealth Prescribing of Evenity in Hawaii

Hawaii permits telehealth prescribing of Evenity. The state's telehealth laws, updated during and after the COVID-19 pandemic, allow licensed prescribers to evaluate patients and prescribe medications, including specialty drugs, via video or audio-visual consultation. This is particularly relevant for patients on neighbor islands (Maui, Kauai, the Big Island, Molokai, Lanai) who may not have convenient access to an endocrinologist or osteoporosis specialist.

The prescribing visit can occur via telehealth, but the actual injections still require an in-person clinical visit. Patients need access to a clinic, infusion center, or provider office for the monthly subcutaneous injections. On neighbor islands, this may mean visiting a primary care office rather than a specialist clinic.

The ARCH trial demonstrated that romosozumab 210 mg monthly for 12 months followed by alendronate reduced the risk of new vertebral fracture by 73% and hip fracture by 38% compared to alendronate alone at 24 months [2]. These outcomes data support the clinical rationale for ensuring access across all of Hawaii's islands, not just Oahu.

Strategies to Lower Your Evenity Cost in Hawaii

Several approaches can reduce out-of-pocket spending for Evenity in Hawaii:

Manufacturer co-pay card. The Amgen/UCB savings program can bring co-pays to $0 for commercially insured patients. This is the single most impactful cost reduction tool for eligible individuals.

Prior authorization appeals. If an initial PA is denied, appeal with supporting documentation. Include DXA results, FRAX scores, fracture history, and cite the Endocrine Society guideline [3] and AACE/ACE 2020 clinical practice guidelines recommending anabolic-first therapy for very high-risk patients.

Specialty pharmacy comparison. Prices at Hawaii specialty pharmacies cluster around the $1,825 list price, but some national specialty pharmacies that ship to Hawaii may negotiate slightly different rates. Ask your insurer which in-network specialty pharmacies are available.

Patient assistance programs. Amgen offers a separate patient assistance program (distinct from the co-pay card) for uninsured or underinsured patients who meet income criteria. This program may provide Evenity at no cost.

Timing the out-of-pocket maximum. If you have other significant medical expenses in a calendar year, consider starting Evenity treatment in a year when you are likely to hit your annual out-of-pocket maximum early. Once the maximum is reached, subsequent Evenity doses may be covered at 100%.

Transition planning. Because Evenity is limited to 12 monthly doses, plan with your prescriber for the antiresorptive agent (typically denosumab or a bisphosphonate) that will follow. The FRAME trial extension showed that patients who transitioned from romosozumab to denosumab continued to gain bone mineral density, with 10.6% BMD increase at the lumbar spine and 5.2% at the total hip at 36 months [6]. Gaps in treatment after romosozumab can lead to rapid bone loss.

Cardiovascular Safety Considerations

Evenity's FDA label carries a boxed warning regarding potential increased risk of myocardial infarction, stroke, and cardiovascular death. In the ARCH trial, major adverse cardiac events (MACE) occurred in 2.5% of romosozumab-treated patients versus 1.9% in the alendronate group during the first 12 months [2]. The difference was not statistically significant for individual endpoints, but the numerical imbalance led to the boxed warning.

The FDA label states that Evenity should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [7]. Prescribers in Hawaii should screen cardiovascular risk factors before initiating therapy. For patients with established cardiovascular disease, the risk-benefit calculus may favor alternative anabolic agents such as teriparatide or abaloparatide, which do not carry the same cardiovascular signal.

This safety profile is relevant to cost discussions because it narrows the eligible patient population. A patient who undergoes the prior authorization process only to be deemed ineligible on cardiovascular grounds faces both wasted time and potential delays in starting an alternative treatment.